Listeria-based cancer vaccines that segregate immunogenicity from toxicity
about
Mesothelin targeted cancer immunotherapyVaccines for pancreatic cancerAntigen-specific immunotherapy of cervical and ovarian cancerNonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunopreventionInterplay between CD8α+ dendritic cells and monocytes in response to Listeria monocytogenes infection attenuates T cell responsesThe intestinal microbiome and surgical disease.Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.Suppression of autoimmune demyelinating disease by preferential stimulation of CNS-specific CD8 T cells using Listeria-encoded neuroantigen.An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.Mesothelin Immunotherapy for Cancer: Ready for Prime Time?A Listeria monocytogenes-based vaccine that secretes sand fly salivary protein LJM11 confers long-term protection against vector-transmitted Leishmania major.Radiation therapy combined with Listeria monocytogenes-based cancer vaccine synergize to enhance tumor control in the B16 melanoma modelAttenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis.Conditional lethality yields a new vaccine strain of Listeria monocytogenes for the induction of cell-mediated immunityPathogenicity and immunogenicity of a vaccine strain of Listeria monocytogenes that relies on a suicide plasmid to supply an essential gene product.Inflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional toleranceGlycolipid antigens for treating hepatic colorectal cancer metastases and their effect on the therapeutic efficacy of live attenuated Listeria monocytogenesYogi Berra, Forrest Gump, and the discovery of Listeria actin comet tails.Investigational approaches for mesothelioma.Dendritic-cell-based therapeutic cancer vaccinesRhamnose-inducible gene expression in Listeria monocytogenes.Tolerance is established in polyclonal CD4(+) T cells by distinct mechanisms, according to self-peptide expression patterns.A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly.Directed antigen delivery as a vaccine strategy for an intracellular bacterial pathogen.Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenesListeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer.Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers.Attenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus.The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumorVaginal protection and immunity after oral immunization of mice with a novel vaccine strain of Listeria monocytogenes expressing human immunodeficiency virus type 1 gag.Intranasal vaccination with the recombinant Listeria monocytogenes ΔactA prfA* mutant elicits robust systemic and pulmonary cellular responses and secretory mucosal IgA.Live bacterial vaccine vectors: an overview.Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapyInflammasome-mediated inhibition of Listeria monocytogenes-stimulated immunity is independent of myelomonocytic functionSTING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes.Absence of vasoactive intestinal peptide expression in hematopoietic cells enhances Th1 polarization and antiviral immunity in miceA novel model for IFN-γ-mediated autoinflammatory syndromes.Cytosolic entry controls CD8+-T-cell potency during bacterial infection.Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
P2860
Q24656242-2EC56A7A-9E16-49BA-8350-4B248F56F920Q26825850-7E48CE4E-9649-4546-AF9E-44E1293A7AE6Q27488697-29DA3425-3D3E-46D1-AFA7-47A37C5A5335Q28082487-A3258EB7-78BF-4453-B26B-4316672372B6Q28740555-C4710996-A79B-4B77-B566-B49B69D862FEQ30248605-9781A0A5-C713-4F12-A82C-DD88AAB876F2Q33633839-7AFF0F5E-3E25-4525-A9CA-D6B532E9238AQ33671350-0F398E62-4131-4157-A68F-A14583AA8145Q33685980-DB15303D-601E-46E8-A52C-D97C5128BB16Q33773435-D212187C-3C17-4C3A-BDAA-80549B3C400FQ33816551-6618CCA2-1BC3-4BBE-B395-C0380A2633D4Q33899733-EE6B21F7-66A2-44F1-9A82-F4FBE93CA40EQ33930599-6F08B19D-7D7F-4DF6-9FA0-C99E39D9DC81Q33930609-225B504F-CF9F-44BC-AC5A-27D17584F768Q33946547-B73DF45E-C5E4-4885-9FC3-D4F9BEA23DE9Q34033905-236BBE5D-436B-4850-A424-24BA596C851BQ34066709-25F42E8D-035E-4F2A-BBB6-76F714F59798Q34089577-FC9430E3-DF39-4190-902F-B19D1BAF48E2Q34213677-DEE12EEB-CD2C-47D6-8B75-098923D13AB1Q34293068-4E7FC1A5-C6F0-428D-8228-D0E598A1F77DQ34360094-A71FC58A-3960-4FCC-BCF1-359C1B2E9B22Q34395693-5DE4909C-B984-4129-87C8-4D28F8D3B70FQ34507271-DF806016-1134-46B7-B5AA-2EAC3A222570Q34575993-95908BBB-6B20-4B30-B7B4-34FE09ADFF8FQ34596940-32AA76EE-7248-4236-9948-843AA2084F77Q34721021-49CCBDC7-8AAB-4079-8536-A2826174567DQ34797653-170A3A6D-C84B-4B8C-8881-DD78C87C4227Q34861112-6136D985-42CB-4F6C-8540-3D6389552DC5Q34871958-DE8C195F-C90D-48FF-AF4B-E3E72487236FQ34920369-A2DC81CB-3D96-4B14-86A9-DE7E2CEF1CCDQ35024249-E1DF9D19-F8F3-4476-B900-A2604D3A6F72Q35066276-92126BC9-09D5-4E17-9A83-C1AA61BA0A0AQ35068970-8066BB2D-5B5E-4641-8FCB-AC620D696ED4Q35069876-D0C46E3A-7B21-4B14-9F2C-262C22B246B6Q35070801-1D7AD26E-7D05-45AB-9F73-BA5FB33557E3Q35082223-AD9E1CE9-0358-441D-94DA-23EE24C02E8EQ35094493-5670921C-9EC8-498B-A7EA-8648E3EFBD2EQ35110844-B0C32B9A-BFCC-4523-B903-5F9B29F8CB3CQ35217477-24757331-E517-45DC-97EA-16531DB662B7Q35419821-45BDE448-6961-460A-B397-DFF76DABA7A7
P2860
Listeria-based cancer vaccines that segregate immunogenicity from toxicity
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 September 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Listeria-based cancer vaccines that segregate immunogenicity from toxicity
@en
Listeria-based cancer vaccines that segregate immunogenicity from toxicity.
@nl
type
label
Listeria-based cancer vaccines that segregate immunogenicity from toxicity
@en
Listeria-based cancer vaccines that segregate immunogenicity from toxicity.
@nl
prefLabel
Listeria-based cancer vaccines that segregate immunogenicity from toxicity
@en
Listeria-based cancer vaccines that segregate immunogenicity from toxicity.
@nl
P2093
P2860
P356
P1476
Listeria-based cancer vaccines that segregate immunogenicity from toxicity
@en
P2093
Daniel A Portnoy
David N Cook
Dirk G Brockstedt
Keith S Bahjat
Martin A Giedlin
Meredith L Leong
Thomas W Dubensky
Weiqun Liu
William Luckett
P2860
P304
13832-13837
P356
10.1073/PNAS.0406035101
P407
P577
2004-09-13T00:00:00Z